Mucosal vaccine based on attenuated influenza virus and the group B Streptococcus recombinant peptides protected mice from influenza and S. pneumoniae infections

Standard

Mucosal vaccine based on attenuated influenza virus and the group B Streptococcus recombinant peptides protected mice from influenza and S. pneumoniae infections. / Desheva, Yulia; Leontieva, Galina; Kramskaya, Tatiana; Grabovskaya, Kornelia B; Karev, Vadim; Mamontov, Andery; Nazarov, Petr ; Suvorov, Alexander.

в: PLoS ONE, Том 14, № 6, e0218544, 25.06.2019, стр. e0218544.

Результаты исследований: Научные публикации в периодических изданиях › статья › Рецензирование

BibTeX

@article{71b5bd0b3f144bf4a352691eba0a9cc9,

title = "Mucosal vaccine based on attenuated influenza virus and the group B Streptococcus recombinant peptides protected mice from influenza and S. pneumoniae infections",

abstract = "Although many influenza-related deaths are attributable to secondary bacterial infection with S. pneumoniae, vaccines that simultaneously protect against influenza and pneumococcal infection are currently not developed. The aim of our study was to evaluate the possibility to prevent post-influenza pneumococcal infection using an associated vaccine based on live influenza vaccine (LAIV) combined with recombinant polypeptides derived from superficial factors of Group B streptococcus (GBS) determining pathogenicity. We demonstrated in a model of post-influenza pneumococcal pneumonia that intranasal pneumococcal super-infection seriously complicated the course of A/Shanghai/2/2013(H7N9) CDC-RG virus infection in mice. Associated immunization using LAIV and GBS vaccine (GBSV) prevented post-influenza pneumococcal pneumonia better than mono-LAIV or GBSV immunization. At the same time, parenteral pneumococcal post-influenza infection of immune mice was more severe in the groups immunized using recombinant GBS peptides which can be explained by antibody-dependent enhancement of infection. In this case, the introduction of blockers of histamine receptors type 1 and 2 reduced the burden of secondary pneumococcal infection.",

keywords = "ANTIBODY-DEPENDENT ENHANCEMENT, PNEUMOCOCCAL PNEUMONIA, LETHAL SYNERGISM, MOUSE MODEL, PATHOGENESIS, EFFICACY, ANTIGEN, PROTEIN",

author = "Yulia Desheva and Galina Leontieva and Tatiana Kramskaya and Grabovskaya, {Kornelia B} and Vadim Karev and Andery Mamontov and Petr Nazarov and Alexander Suvorov",

year = "2019",

month = jun,

day = "25",

doi = "10.1371/journal.pone.0218544",

language = "Английский",

volume = "14",

pages = "e0218544",

journal = "PLoS ONE",

issn = "1932-6203",

publisher = "Public Library of Science",

number = "6",

}

RIS

TY - JOUR

T1 - Mucosal vaccine based on attenuated influenza virus and the group B Streptococcus recombinant peptides protected mice from influenza and S. pneumoniae infections

AU - Desheva, Yulia

AU - Leontieva, Galina

AU - Kramskaya, Tatiana

AU - Grabovskaya, Kornelia B

AU - Karev, Vadim

AU - Mamontov, Andery

AU - Nazarov, Petr

AU - Suvorov, Alexander

PY - 2019/6/25

Y1 - 2019/6/25

N2 - Although many influenza-related deaths are attributable to secondary bacterial infection with S. pneumoniae, vaccines that simultaneously protect against influenza and pneumococcal infection are currently not developed. The aim of our study was to evaluate the possibility to prevent post-influenza pneumococcal infection using an associated vaccine based on live influenza vaccine (LAIV) combined with recombinant polypeptides derived from superficial factors of Group B streptococcus (GBS) determining pathogenicity. We demonstrated in a model of post-influenza pneumococcal pneumonia that intranasal pneumococcal super-infection seriously complicated the course of A/Shanghai/2/2013(H7N9) CDC-RG virus infection in mice. Associated immunization using LAIV and GBS vaccine (GBSV) prevented post-influenza pneumococcal pneumonia better than mono-LAIV or GBSV immunization. At the same time, parenteral pneumococcal post-influenza infection of immune mice was more severe in the groups immunized using recombinant GBS peptides which can be explained by antibody-dependent enhancement of infection. In this case, the introduction of blockers of histamine receptors type 1 and 2 reduced the burden of secondary pneumococcal infection.

AB - Although many influenza-related deaths are attributable to secondary bacterial infection with S. pneumoniae, vaccines that simultaneously protect against influenza and pneumococcal infection are currently not developed. The aim of our study was to evaluate the possibility to prevent post-influenza pneumococcal infection using an associated vaccine based on live influenza vaccine (LAIV) combined with recombinant polypeptides derived from superficial factors of Group B streptococcus (GBS) determining pathogenicity. We demonstrated in a model of post-influenza pneumococcal pneumonia that intranasal pneumococcal super-infection seriously complicated the course of A/Shanghai/2/2013(H7N9) CDC-RG virus infection in mice. Associated immunization using LAIV and GBS vaccine (GBSV) prevented post-influenza pneumococcal pneumonia better than mono-LAIV or GBSV immunization. At the same time, parenteral pneumococcal post-influenza infection of immune mice was more severe in the groups immunized using recombinant GBS peptides which can be explained by antibody-dependent enhancement of infection. In this case, the introduction of blockers of histamine receptors type 1 and 2 reduced the burden of secondary pneumococcal infection.

KW - ANTIBODY-DEPENDENT ENHANCEMENT

KW - PNEUMOCOCCAL PNEUMONIA

KW - LETHAL SYNERGISM

KW - MOUSE MODEL

KW - PATHOGENESIS

KW - EFFICACY

KW - ANTIGEN

KW - PROTEIN

UR - http://www.scopus.com/inward/record.url?scp=85068870482&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0218544

DO - 10.1371/journal.pone.0218544

M3 - статья

C2 - 31237893

VL - 14

SP - e0218544

JO - PLoS ONE

JF - PLoS ONE

SN - 1932-6203

IS - 6

M1 - e0218544

ER -

ID: 45926245